[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100439616":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":39,"responsibleParty":56,"collaborators":12,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":12,"enrollmentInfo":67,"targetDuration":12,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":78,"overallStatus":42,"whyStopped":12,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Erasme University Hospital","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"standard of care","NO_INTERVENTION","Patients will receive the standard of care infusion (balanced crystalloids)",null,{"label":14,"type":15,"description":16,"interventionNames":17},"treatement group","EXPERIMENTAL","Sodium lactate infusion 15 µmol\u002FKg\u002Fmin",[18],"Drug: Sodium Lactate Solution",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Sodium Lactate Solution","continuous intravenous infusion of molar sodium lactate",[14],[26],"Hyperonic sodium lactate",[28],{"name":29,"affiliation":5,"role":30},"Filippo Annoni, MD","PRINCIPAL_INVESTIGATOR",[32,36],{"name":29,"role":33,"phone":34,"phoneExt":12,"email":35},"CONTACT","0483141483","filippo.annoni@erasme.ulb.ac.be",{"name":37,"role":33,"phone":12,"phoneExt":12,"email":38},"Fabio S Taccone, MD,PhD","fabio.tacconei@erasme.ulb.ac.be",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":44,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Erasme Hospital, Brussels University Hospital (HUB)","RECRUITING","Brussels","Belgium","1070","BE",{"type":48,"coordinates":49},"Point",[50,51],4.34878,50.85045,{"lat":51,"lon":50},[54],{"name":55,"role":30,"phone":12,"phoneExt":12,"email":12},"Fabio Silvio Taccone, MD, PhD",{"type":57,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100439616","phase-2-hypertonic-lactate-after-cardiac-arrest-100439616",false,"NCT05004610","Hypertonic Lactate After Cardiac Arrest","LATTE","Inclusion Criteria:\n\n* Age \\> 18 years old\n* Sustained (\\> 20 minutes) return of spontaneous circulation (ROSC)\n* Comatose (GCS \\\u003C 9)\n* Time to ROSC \\> 15'\n\nExclusion Criteria:\n\n* Protected categories (Pregnant women)\n* Anticipated withdrawal of support within 24 hours\n* Traumatic cause of cardiac arrest\n* Body weight at admission \\> 120Kg","ALL","18 Years",{"count":68,"type":69},125,"ESTIMATED","INTERVENTIONAL",[72],"PHASE2","The study is intended to test the hypothesis that sodium lactate infusion after resuscitation from a cardiac arrest will decrease the magnitude of brain damage, as measured by the serum biomarker concentration of NSE.",[75,76,77],"Cardiac Arrest","Ischemia Reperfusion Injury","Anoxic Brain Injury",[79,80],"sodium lactate","cerebral metabolism","2025-02-20",{"date":83,"type":84},"2025-02-21","ACTUAL",{"date":86,"type":84},"2025-02-19",{"date":88,"type":69},"2028-05-15",{"name":5,"class":6},1]